Trendlyne Blog: , Latest on stock market and finance in India and the world.

22 Mar 2023

497.40

-3.59%

Buy Zydus Lifesciences; target of Rs 572: Sharekhan

Moneycontrol

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 572 in its research report dated March 21, 2023.

Sharekhan increased Buy price target of Zydus Wellness Ltd. to 2688.0 on 03 Sep, 2025.

Zydus Lifesciences shares gain following USFDA approval for Tofacitinib tablets

Moneycontrol | 22 Mar 2023, 09:32AM

Britannia Industries Ltd.

20 Mar 2023

6084.50

0.25%

Rural recovery, price cuts to drive volume gains for consumer companies

Business Standard

It's 'rule Britannia' for brokerages; analysts divided on extent of margin gains

Britannia Industries Ltd. has gained 26.39% in the last 6 Months

Britannia Industries Ltd.

16 Mar 2023

6084.50

0.25%

Britannia's Croissant business crosses 100 crore revenue

Business Line

Treat Croissant is manufactured at Britannia's own manufacturing facility, and the recipe has been customised to cater to the Indian palette.

Britannia Industries.. has an average target of 5824.71 from 7 brokers.

Zydus Wellness Ltd.

08 Mar 2023

497.40

-3.59%

Zydus Lifesciences gets final USFDA approval for cancer drug; shares flat

Moneycontrol

Lenalidomide Capsules works by slowing or stopping the growth of cancer cells.

Zydus Wellness Ltd. has gained 49.14% in the last 6 Months

Britannia Industries Ltd.

06 Mar 2023

6084.50

0.25%

Cookie may crumble for Britannia as soaring wheat, milk prices to crimp margins: CLSA

Moneycontrol

CLSA has downgraded Britannia from Underperform to Sell rating and has cut target price on the stock

Number of FII/FPI investors increased from 885 to 948 in Jun 2025 qtr.

Britannia Industries Ltd.

05 Mar 2023

6084.50

0.25%

Britannia looks to increase its women workforce to 50% from 41% by 2024

Business Standard

FMCG major Britannia Industries is aiming to increase its women workforce to 50 per cent from the present 41 per cent by 2024, a senior company official said on Sunday. With 15 company-owned manufacturing plants and 35 contract and franchisee units across India having a workforce of over one lakh people, Britannia currently has 41 per cent women employees and would increase the strength to 50 per cent by the end of 2024, Head of Manufacturing, Owned Factories, Indranil Gupta said. The company has about 1,400 workers in its Madurai unit of which 65 per cent comprise women, Gupta said. The female workforce in the plant will be increased to 70 per cent by 2024, since it produced 190 tonnes of various food products per day, the senior official told journalists. When asked about the reason behind pushing for more women employees, Gupta said: "They are more hygienic, and more suitable for these type of jobs, which is an important requirement in food making facilities and disciplined...

Axis Direct upgraded Britannia Industries Ltd. to Buy with a price target of 6750.0 on 05 Sep, 2025.

Zydus Wellness Ltd.

28 Feb 2023

497.40

-3.59%

Zydus Lifesciences receives USFDA approval to market generic drug

Business Standard

Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to market a generic medication to prevent and treat blood clots. The company has received approval from the US Food and Drug Administration (USFDA) to market Apixaban tablets in strengths of 2.5 and 5 mg, according to a regulatory filing. Apixaban blocks the activity of certain clotting substances in the blood. It is used to lower the risk of stroke or a blood clot in people with a heart rhythm disorder called atrial fibrillation. It is also used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery. The drug will be manufactured at the Zydus group's formulation manufacturing facility at Moraiya, Ahmedabad. As per IQVIA MAT December 2022 data, Apixaban tablets had annual sales of USD 18,876 million in the US.

Zydus Wellness Ltd. has gained 49.14% in the last 6 Months

Nestle India Ltd.

22 Feb 2023

1196.20

0.14%

Accumulate Nestle India; target of Rs 21,805: KR Choksey

Moneycontrol

KR Choksey recommended accumulate rating on Nestle India with a target price of Rs 21,805 in its research report dated February 20, 2023.

Axis Direct increased Buy price target of Nestle India Ltd. to 1340.0 on 05 Sep, 2025.

Zydus Wellness Ltd.

20 Feb 2023, 05:38PM

497.40

-3.59%

Zydus Lifesciences gets US health regulator nod for generic products

Business Standard

Zydus Lifesciences on Monday said it has received approval from the US health regulator to market generic medicines in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market Gabapentin tablets which are indicated for the management of postherpetic neuralgia (PHN). As per IQVIA MAT data, the medication had annual sales of USD 90 million in the US. The company said it also has received approval from the US health regulator for diabetes drug Canagliflozin and Metformin Hydrochloride tablets. As per IQVIA MAT data, Canagliflozin and Metformin Hydrochloride tablets had annual sales of USD 49.4 million in the US. Shares of the company on Monday ended 1.36 per cent down at Rs 464.15 apiece on the BSE.

Zydus Wellness Ltd. has gained 24.21% in the last 3 Months

Nestle India Ltd.

20 Feb 2023, 04:26PM

1196.20

0.14%

Broker's Call: Nestle India (Add)

Business Line

ICICI Securities

Number of FII/FPI investors decreased from 902 to 873 in Jun 2025 qtr